<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: Re: Performance enhancement with donepezil</title>
<meta name="Author" content="Alex Ramonsky (alex@ramonsky.com)">
<meta name="Subject" content="Re: Performance enhancement with donepezil">
<meta name="Date" content="2003-01-29">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>Re: Performance enhancement with donepezil</h1>
<!-- received="Wed Jan 29 23:22:58 2003" -->
<!-- isoreceived="20030130062258" -->
<!-- sent="Thu, 30 Jan 2003 06:29:46 +0000" -->
<!-- isosent="20030130062946" -->
<!-- name="Alex Ramonsky" -->
<!-- email="alex@ramonsky.com" -->
<!-- subject="Re: Performance enhancement with donepezil" -->
<!-- id="3E38C65A.4030000@ramonsky.com" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="BMEDJIBJGLNDOOANGIDLCEFNCJAA.rms2g@virginia.edu" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Alex Ramonsky (<a href="mailto:alex@ramonsky.com?Subject=Re:%20Performance%20enhancement%20with%20donepezil"><em>alex@ramonsky.com</em></a>)<br>
<strong>Date:</strong> Wed Jan 29 2003 - 23:29:46 MST
</p>
<!-- next="start" -->
<ul>
<li><strong>Next message:</strong> <a href="1642.html">Kai Becker: "Re: Internet and defamation laws (was Re: Oil Economics)"</a>
<li><strong>Previous message:</strong> <a href="1640.html">Alex Ramonsky: "Re: Performance enhancement with donepezil"</a>
<li><strong>In reply to:</strong> <a href="1611.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1649.html">gts: "Re: Performance enhancement with donepezil"</a>
<li><strong>Reply:</strong> <a href="1649.html">gts: "Re: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1641">[ date ]</a>
<a href="index.html#1641">[ thread ]</a>
<a href="subject.html#1641">[ subject ]</a>
<a href="author.html#1641">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Rafal Smigrodzki wrote:
<br>
[of Deprenyl)
<br>
<p><em>&gt;## How does it compare to MAOI's?
</em><br>
<em>&gt;
</em><br>
<em>&gt;It's not a coincidence that MAOI's are third-line antidepressants - they are
</em><br>
<em>&gt;too risky and not sufficiently effective compared to SSRI's, TCA's, and
</em><br>
<em>&gt;atypicals.
</em><br>
<em>&gt;
</em><br>
...er guys...am I missing something here?
<br>
...Deprenyl Hydrochloride _is_ an MAOI.
<br>
<p>It's a monoamine oxidase B inhibitor.
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="1642.html">Kai Becker: "Re: Internet and defamation laws (was Re: Oil Economics)"</a>
<li><strong>Previous message:</strong> <a href="1640.html">Alex Ramonsky: "Re: Performance enhancement with donepezil"</a>
<li><strong>In reply to:</strong> <a href="1611.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1649.html">gts: "Re: Performance enhancement with donepezil"</a>
<li><strong>Reply:</strong> <a href="1649.html">gts: "Re: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1641">[ date ]</a>
<a href="index.html#1641">[ thread ]</a>
<a href="subject.html#1641">[ subject ]</a>
<a href="author.html#1641">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sun Feb 02 2003 - 21:26:03 MST
</em></small></p>
</body>
</html>
